From her perch at Navitus, Crosson has become a prominent advocate on PBM transparency and prescription drug affordability issues, frequently speaking with policymakers, industry groups, and healthcare stakeholders about legislative reforms and regulatory trends.
Savasta welcomes the new transparency rules for pharmacy benefit managers because "transparency has always been a core component of our business model."
The move toward integrating HIV services with other healthcare services was already underway before the PEPFAR cuts, says Warren, executive director of AVAC.
Zambia's infectious disease director says data and specimen sharing, not mineral rights, are what's holding up its still-unsigned U.S. health memorandum of understanding.
Like Journavx, LTG-001 is a Nav1.8 inhibitor that is designed to selectively block the transmission of pain without the risk of addiction.
CMS said its Medicaid Fraud War Room suspended more than $203 million in improper payments and flagged 50 high-risk providers in its first 88 days of operation.
It is not surprising that it is taking some time for injectable lenacapavir for PrEP to catch, an Emory Univeristy researchers say the patterns of use in the early months of lenacapavir's availability are similar to inequities seen with older versions of PrEP.
Children using virtual reality needed significantly lower nitrous oxide concentrations during Botox procedures, potentially reducing side effects like nausea, vomiting, and hallucinations, researchers reported.
CMS has set the 2027 Part D bid amount at $296.05 and will end its premium stabilization demonstration, raising cost questions for 25 million enrollees.
Specialty drug spend is being driven by utilization, while the non-specialty trend is being pushed up as a result of the use of GLP-1s for diabetes and for weight loss.
Lowering the dose of islatravir from 20 milligrams to two seems to have solved problem of sinking CD4+ T cell counts.
Community-led programs across four countries show gains in HIV retention, mental health and service uptake among people who engage in chemsex.
Questions about price and access hover over the positive results for a weekly HIV treatment pill that combines Merck’s islatravir and Gilead’s lenacapavir.
Data presented at the International AIDS Conference 2026 show Cabenuva reduced viral rebound in adolescents versus oral therapy, but access to long-acting injectables remains limited where need is greatest, investigators said.
Raphael J. Landovitz, M.D., of UCLA, says HIV prevention science has surged ahead of the world's ability to deliver it.
Raphael J. Landovitz, M.D., says rare lenacapavir breakthrough infections raise new questions about how often patients need testing between PrEP doses.
Raphael J. Landovitz, M.D., of UCLA says surveillance gaps, Medicaid nonexpansion states and injectable pricing are stalling U.S. PrEP uptake.
Zambia's director of infectious disease spoke about the pared-down "basic minimum package" now adopted in Malawi, Mozambique and Kenya as U.S. funding for HIV response tightened.
Real-world CAPTIVATE study of 241 CAB LA users found no HIV acquisitions, 99% satisfaction and 97% preference over oral PrEP.
Researchers report positive results from open-label extension studies amid looming concerns that the long-acting injectable won’t be available where it is needed.
The lack of a standard, clear approach to present prices to consumers is a big reason why healthcare costs keep rising.
Disbursements for the HIV response dropped by 25% from 2024 to 2025
In the VOGUE trial, Dovato matched Biktarvy at week 48, demonstrating that it was noninferior in HIV-1 viral suppression in treatment-naive adults, including high-risk patients.
Metformin, topiramate and three GLP-1 receptor agonists ranked as the most effective options for managing antipsychotic-induced weight gain, according to a new study published in JAMA Psychiatry.
The approval of centanafadine, now with the brand name, Simtriyo, introduces a new treatment approach for adults and children with ADHD.
Consumers are reshaping healthcare faster than the industry can adapt.
A once-weekly oral HIV treatment could make a major difference in resource-constrained settings, says the executive director of AVAC.
People are beginning to fall out of treatment because of the PEPFAR funding cuts but the infrastructure of the programs has survived, says the executive director off AVAC, a U.S. organization that advocates for HIV prevention.
AVAC Executive Director Mitchell Warren says HIV prevention science has never been stronger, even as funding cuts have left program infrastructure badly weakened.
Renee Heffron, Ph.D., M.P.H., of the University of Alabama at Birmingham, says the HIV field has found new collaborations and funders after major disruptions in U.S. funding and cannot afford to lose ground on prevention.
